BioLineRx Ltd (BLRX)

[midastouch017]

BioLineRx Ltd. (NASDAQ:BLRX)
No. of Hedge Fund Holders: 5

https://finance.yahoo.com/news/11-best-stocks-long-term-083813941.html

BioLineRx Ltd. (NASDAQ: BLRX) is a biopharmaceutical firm specializing in oncology. The company is seventh on our list of 11 best stocks for long term growth

On May 4, investment advisory Maxim kept a Buy rating on BioLineRx Ltd. (NASDAQ: BLRX) stock and raised the price target to $10 from $5, following announcement of top-line results from the company.

In May, BioLineRx Ltd. (NASDAQ: BLRX) reported convincing results from the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization in patients suffering from multiple myeloma. In response to the positive results, the stock rocketed over 100%. The company is trying to submit a non-disclosure agreement (NDA). If approved the company will have a commercial stage molecule in stem cell mobilization (SCM).

BioLineRx Ltd. (NASDAQ: BLRX) had $66 million in cash and cash equivalents at the end of the second quarter of 2021. Research and development expenses at the end of the second quarter of 2021 were $5.1 million, up $0.5 million compared to $4.6 million in the same period last year.

Our data shows that Parkman Healthcare Partners is one of the biggest stakeholders of BioLineRx Ltd. (NASDAQ: BLRX) with 734,032 shares worth $2.1 million